The post Strive’s Semler Buy Likely to Start Next Wave of Digital Asset Treasuries M&A appeared on BitcoinEthereumNews.com. The world of Digital Asset Treasury (DATs) has entered a new era, after Strive (ASST) announced an all-stock deal to acquire Semler Scientific (SMLR) this week. The deal marked the first merger of two publicly traded bitcoin treasuries, and according to a Wall Street banker familiar with the situation, this is just the start of a massive consolidation wave among the DATs. The banker, who opted to remain anonymous, outlined three scenarios for how DATS may evolve. Mergers to add more BTC The first of the three paths is the DAT-to-DAT mergers. Strive’s acquisition of Semler is the first clear example of unifying BTC holdings, boosting bitcoin per share, and establishing governance under one roof, the banker said. When it closes, the deal will create a new company that will hold nearly 11,000 BTC after Strive’s simultaneous $675 million purchase of 5,885 coins. It’s worth noting that Semler’s shares had been trading below the value of its bitcoin, effectively assigning negative value to its medical device business. For Strive, the acquisition consolidates balance sheets, adds BTC scale, and pushes forward a key company metric: Bitcoin per share. “Strive’s merger announcement is accretive in bitcoin per share, meeting our short-term goal,” CEO Matt Cole wrote on X. “We believe the combined power of the entities will give the combined company more ability to access the capital markets in a way that will drive increased bitcoin per share and accretion in a way neither could do on their own.” With the bitcoin treasury market being saturated with many publicly traded companies, this strategy is likely to be one of the most efficient ways to grow for the DATs. The cash-flow angle The banker said the second path of evolution is acquiring cash-flowing businesses to offset dilution and fund ongoing BTC purchases. Metaplanet,… The post Strive’s Semler Buy Likely to Start Next Wave of Digital Asset Treasuries M&A appeared on BitcoinEthereumNews.com. The world of Digital Asset Treasury (DATs) has entered a new era, after Strive (ASST) announced an all-stock deal to acquire Semler Scientific (SMLR) this week. The deal marked the first merger of two publicly traded bitcoin treasuries, and according to a Wall Street banker familiar with the situation, this is just the start of a massive consolidation wave among the DATs. The banker, who opted to remain anonymous, outlined three scenarios for how DATS may evolve. Mergers to add more BTC The first of the three paths is the DAT-to-DAT mergers. Strive’s acquisition of Semler is the first clear example of unifying BTC holdings, boosting bitcoin per share, and establishing governance under one roof, the banker said. When it closes, the deal will create a new company that will hold nearly 11,000 BTC after Strive’s simultaneous $675 million purchase of 5,885 coins. It’s worth noting that Semler’s shares had been trading below the value of its bitcoin, effectively assigning negative value to its medical device business. For Strive, the acquisition consolidates balance sheets, adds BTC scale, and pushes forward a key company metric: Bitcoin per share. “Strive’s merger announcement is accretive in bitcoin per share, meeting our short-term goal,” CEO Matt Cole wrote on X. “We believe the combined power of the entities will give the combined company more ability to access the capital markets in a way that will drive increased bitcoin per share and accretion in a way neither could do on their own.” With the bitcoin treasury market being saturated with many publicly traded companies, this strategy is likely to be one of the most efficient ways to grow for the DATs. The cash-flow angle The banker said the second path of evolution is acquiring cash-flowing businesses to offset dilution and fund ongoing BTC purchases. Metaplanet,…

Strive’s Semler Buy Likely to Start Next Wave of Digital Asset Treasuries M&A

The world of Digital Asset Treasury (DATs) has entered a new era, after Strive (ASST) announced an all-stock deal to acquire Semler Scientific (SMLR) this week.

The deal marked the first merger of two publicly traded bitcoin treasuries, and according to a Wall Street banker familiar with the situation, this is just the start of a massive consolidation wave among the DATs.

The banker, who opted to remain anonymous, outlined three scenarios for how DATS may evolve.

Mergers to add more BTC

The first of the three paths is the DAT-to-DAT mergers.

Strive’s acquisition of Semler is the first clear example of unifying BTC holdings, boosting bitcoin per share, and establishing governance under one roof, the banker said.

When it closes, the deal will create a new company that will hold nearly 11,000 BTC after Strive’s simultaneous $675 million purchase of 5,885 coins.

It’s worth noting that Semler’s shares had been trading below the value of its bitcoin, effectively assigning negative value to its medical device business. For Strive, the acquisition consolidates balance sheets, adds BTC scale, and pushes forward a key company metric: Bitcoin per share.

“Strive’s merger announcement is accretive in bitcoin per share, meeting our short-term goal,” CEO Matt Cole wrote on X.

“We believe the combined power of the entities will give the combined company more ability to access the capital markets in a way that will drive increased bitcoin per share and accretion in a way neither could do on their own.”

With the bitcoin treasury market being saturated with many publicly traded companies, this strategy is likely to be one of the most efficient ways to grow for the DATs.

The cash-flow angle

The banker said the second path of evolution is acquiring cash-flowing businesses to offset dilution and fund ongoing BTC purchases.

Metaplanet, Japan’s largest bitcoin holder, has already said it will use its treasury to buy cash-generating businesses as part of its “phase two” strategy.

Metaplanet is also exploring the use of perpetual preferred stock, a financing strategy that Strategy (MSTR) has already employed, allowing it to buy bitcoin without diluting shareholders through at-the-market (ATM) common stock offerings.

No more SPACs

Third, is merging with legitimate businesses instead of using special-purpose acquisition companies (SPACs), according to the banker.

SPACs are shell firms designed to take companies public quickly, but the “de-SPAC” process can be messy, requiring shareholder votes, regulatory filings, and often suffering from investor redemptions. Making things more complex, to bridge funding gaps, many SPACs rely on PIPEs (private investments in public equity), which bring dilution, discounts and uncertainty.

For DATs, merging directly with a company that already has operations and governance avoids these pitfalls.

The evolution of DATs

The bottom line is that DATs are at a point where they need to evolve and get creative with their growth strategies.

In fact, other companies are already catching on to this trend. Recently, FRNT Financial (TSXV: FRNT), a digital asset investment bank, said it has entered into a consulting agreement with an undisclosed DAT with $100 million worth of digital assets in its balance sheet.

According to the deal terms, FRNT will help evaluate and structure lending opportunities for the company’s next growth phase.

The deals, such as the Strive-Semler merger, show digital asset treasury companies will need to scale through consolidation, buy profitable businesses, or align with established operators that bring legitimacy, ushering in the next phase of DATs’ evolution.

Read more: Semler Scientific Still Has Nearly 170% Upside After Strive Buyout Deal: Benchmark

Source: https://www.coindesk.com/markets/2025/09/28/from-spacs-to-cash-flow-buys-how-dats-are-plotting-the-next-growth-phase

Market Opportunity
MemeCore Logo
MemeCore Price(M)
$1.53656
$1.53656$1.53656
+11.36%
USD
MemeCore (M) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Thị trường tài chính toàn cầu vừa chứng kiến một khoảnh khắc lịch sử chấn động: Giá Vàng thế giới [...] The post Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của
Share
Vneconomics2026/02/10 16:26
Why the Bitcoin Boom Is Not Another Tulip Mania

Why the Bitcoin Boom Is Not Another Tulip Mania

Bitcoin is an amazing success story. It was only invented in January of 2009 and was only worth a tiny fraction of a cent for each token. Over just a few years
Share
Medium2026/02/10 15:44
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26